Related Experiment Video

Updated: Dec 20, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K

Fanconi Anemia Pathway Activation by FOXM1 Is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance

Yun-Gil Roh1, Jeong-Yeon Mun1, Seon-Kyu Kim2,3

  • 1Department of Biological Science, Dong-A University, Busan 49315, Korea.

Cancers
|June 4, 2020
PubMed

Insights

FOXM1 and FANCD2 are key biomarkers for nonmuscle invasive bladder cancer (NMIBC) recurrence. Targeting these genes may improve chemotherapy response and reduce NMIBC cancer recurrence.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Nonmuscle invasive bladder cancer (NMIBC) has a high 5-year survival rate, but over 50% of patients experience frequent recurrences.
  • Identifying molecular targets is crucial for understanding and predicting NMIBC recurrence.
  • The Fanconi anemia (FA) pathway plays a role in DNA repair and chemotherapy resistance.

Purpose of the Study:

  • To identify molecular targets associated with NMIBC recurrence.
  • To investigate the role of FOXM1 and FANCD2 in NMIBC recurrence mechanisms.
  • To evaluate FOXM1 and FANCD2 as potential biomarkers for NMIBC.

Main Methods:

  • Analysis of gene expression data to identify potential molecular targets.
  • Investigating the regulatory relationship between FOXM1 and FANCD2.
  • Assessing the impact of FOXM1 depletion on DNA repair and chemotherapy resistance.

Main Results:

  • FOXM1 and FANCD2 were identified as genes involved in NMIBC recurrence.
  • FOXM1 directly regulates the transcription of FANCD2, a key gene in the FA pathway.
  • FOXM1 depletion led to DNA repair defects and decreased chemotherapy resistance.
  • The FANCD2-associated FA pathway, activated by FOXM1, is implicated in chemotherapy-related recurrence.

Conclusions:

  • FOXM1 and FANCD2 are significant prognostic factors in NMIBC.
  • These genes are associated with a high risk of recurrence and anticancer drug resistance.
  • FOXM1 and FANCD2 represent potential therapeutic targets for improving NMIBC patient outcomes.
Keywords:
DNA repairFANCD2FOXM1Fanconi anemia pathwaybladder cancercancer recurrence

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K
A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.0K